期刊文献+

肾脏病理分级对少量蛋白尿IgA肾病临床治疗的指导意义 被引量:3

原文传递
导出
摘要 IgA肾病临床表现多变,从孤立性血尿到快速进展的肾小球肾炎,进展至肾衰竭的速率也各不相同。临床上IgA肾病的治疗目标是有效降低蛋白尿,控制血压,减少肾组织进一步损伤,维持肾功能稳定。因此,全面的风险评估对于确定治疗方案和平衡治疗风险是必不可少的。KDIGO指南建议用肾脏病理特征评估预后,目前用病理分级作为治疗依据的前瞻性研究报道尚不多。我们采用肾脏病理分级作为少量蛋白尿IgA肾病的治疗依据,对病理分级、积分偏高的IgA肾病患者进行积极治疗,观察IgA肾病患者预后。一。
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2012年第11期900-901,共2页 Chinese Journal of Nephrology
  • 相关文献

参考文献4

  • 1Wilmer WA, Rovin BH, Hebert CJ, et, al. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol, 2003, 14: 3217-3232.
  • 2Brown C, Haddad N, Hebert LA. Retarding progression of kidney disease.//Floege J, Feehally J, Johnson RJ. Comprehensive Clinical Nephrology. 1th. St. Louis: Elsevier, 2010: 919-926.
  • 3Abboud H, Henrich WL. Clinical practice.Stage IV chronic kidney disease. N Engl J Med, 2010, 362: 56-65.
  • 4Eitner F, Ackermann D, Hilgers RD, et al. Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol. J Nephrol, 2008, 21: 284-289.

同被引文献26

  • 1刘刚,马序竹,邹万忠,王梅,王海燕.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21(12):834-838. 被引量:182
  • 2李占亭,杨洁,孙脊峰,杜德伟,刘丽丽,王莉.IgA肾病的治疗进展[J].第四军医大学学报,2007,28(10):952-953. 被引量:11
  • 3Donadio JV,Grande JP.Ig, A nephropathy[J].N EngI J Med,2002(347):738-748.
  • 4Li PKT,Leung CB,Chow KM,et al.Hong Kong study using Valsartan in I- gAN(HKVIN)-A double-blind randomized placebo-con-trolled study[J]. Am J Kidney Dis,2006,47(5):751-760.
  • 5Coppo R,Peruzzi L, Amore A,et al.IgACE:a placebo-eontrolled,rand- omized trial of angotensin-converting enzyme inhibitors in childr- en and young people with IgAN and moderate proteinuria[J].J Am Soc Nephrol,2007,18(6): 1880-1888.
  • 6Yamamoto R,Nagasawa Y,Shoji T,et al.Cigarette smoking and prog- ression of IgA nephropathy[J].Am J Kidney Dis,2010,56(2):313-324.
  • 7Pozzi C,Andrulli S,Del VL,et al.Corticosteroid effectiveness in IgA nephropathy:long-term results of a randomized.controlled trial[J].J Am Soc Nephrol,2004,15(1):157-163.
  • 8KDIGOKGW G.KDIGO Clinical Practice Guideline for Glomer u- lonephritis[J].Kid Int Suppl,20'12,2(2):259-274.
  • 9Tang SC,Tang AW,Wong SS,et al.Long-term Study of mycophenola- te mofetil treatment in IgA nephropathy[J].Kidney Int,2010,77(6): 543-549.
  • 10Liu XW,Linm,Xu Gs,et al.Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immun- oglobulin A nephropathy manifesting with nephritic syndrome[J].Int J Clin pharmacol Ther,2010,48(8):509-513.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部